About this Research Topic
Drug repurposing has become a strategy for identifying approved or investigational drugs so that they can be used outside the scope of the original medical indication. The advantages are a low risk of failure, reduced time frame for development because early-stage trials are completed, and most of the preclinical testing, safety assessment and formulation development are validated. Additionally, less investment is required depending on the stage and process of development of the repurposing candidate.
To address tumor heterogeneity and its rapid molecular evolution, combinatorial approaches to treat cancer are being widely used in clinics. As such it is imperative to increase the armamentarium of available drugs to improve patient outcome. Exploring the utility of pre-existing FDA approved drugs within this space might offer a faster path for clinical implementation rendering it essential to explore drug repurposing and its utility in cancer therapeutics.
This Research Topic will provide a platform to publish research exploring the molecular mechanisms, effects, and efficiency of combinatorial treatments with repurposed drugs in cancer. The collection will also highlight studies that address drug repurposing (also known as drug repositioning) and solicit discussion about the challenges faced by the repurposing research community, and recommendations for innovative ways to address drug development in cancer. Our goal is to ensure the research carried out in this area is well covered and will add value in the form of new information to the existing ones.
This research topic invites original research and review articles involving repurposed drugs in combinatorial drug treatments to inhibit cancer progression including:
• Treatment approaches that specifically target or reduce drug resistance.
• Computational approaches such as signature matching, molecular docking, pathways, and network.
• Molecular mechanisms of combination treatments and therapies in cancer.
• Signature matching providing a new approach to leverage drug-induced expression profiles. could involve transcriptomic, proteomic or metabolomic data.
• Pathway mapping: pathway-based approaches to identify drugs or drug targets.
• Retrospective Clinical analysis as an approach to analyze clinical data.
• Genetic association, Phenotypic screening to combine genotype data to determine the effect of genetic variants on expression.
• Binding assays to identify relevant target interactions.
• Recent advances in single cell analysis and 3D bioprinting within the field of drug re-purposing.
Please note: studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied.
We accept different article types including Mini-Reviews, Brief Research Reports and Perspectives. A full list of accepted article types, including descriptions, can be found at this link.
To address tumor heterogeneity and its rapid molecular evolution, combinatorial approaches to treat cancer are being widely used in clinics. As such it is imperative to increase the armamentarium of available drugs to improve patient outcome. Exploring the utility of pre-existing FDA approved drugs within this space might offer a faster path for clinical implementation rendering it essential to explore drug repurposing and its utility in cancer therapeutics.
This Research Topic will provide a platform to publish research exploring the molecular mechanisms, effects, and efficiency of combinatorial treatments with repurposed drugs in cancer. The collection will also highlight studies that address drug repurposing (also known as drug repositioning) and solicit discussion about the challenges faced by the repurposing research community, and recommendations for innovative ways to address drug development in cancer. Our goal is to ensure the research carried out in this area is well covered and will add value in the form of new information to the existing ones.
This research topic invites original research and review articles involving repurposed drugs in combinatorial drug treatments to inhibit cancer progression including:
• Treatment approaches that specifically target or reduce drug resistance.
• Computational approaches such as signature matching, molecular docking, pathways, and network.
• Molecular mechanisms of combination treatments and therapies in cancer.
• Signature matching providing a new approach to leverage drug-induced expression profiles. could involve transcriptomic, proteomic or metabolomic data.
• Pathway mapping: pathway-based approaches to identify drugs or drug targets.
• Retrospective Clinical analysis as an approach to analyze clinical data.
• Genetic association, Phenotypic screening to combine genotype data to determine the effect of genetic variants on expression.
• Binding assays to identify relevant target interactions.
• Recent advances in single cell analysis and 3D bioprinting within the field of drug re-purposing.
Please note: studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied.
We accept different article types including Mini-Reviews, Brief Research Reports and Perspectives. A full list of accepted article types, including descriptions, can be found at this link.
Keywords: Metastasis, synergistic combinations, Drug Repurposing, Distant metastasis, Multi drug resistance, signaling mechanisms, epigenetic alteration, Invasion, migration.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
